PL4126854T3 - Sposób wytwarzania inhibitorów ferroportyny - Google Patents

Sposób wytwarzania inhibitorów ferroportyny

Info

Publication number
PL4126854T3
PL4126854T3 PL21712874.3T PL21712874T PL4126854T3 PL 4126854 T3 PL4126854 T3 PL 4126854T3 PL 21712874 T PL21712874 T PL 21712874T PL 4126854 T3 PL4126854 T3 PL 4126854T3
Authority
PL
Poland
Prior art keywords
manufacturing
ferroportin inhibitors
ferroportin
inhibitors
manufacturing ferroportin
Prior art date
Application number
PL21712874.3T
Other languages
English (en)
Inventor
Stefan Reim
Erik Philipp
Maria WILHELM
Cyrill BLATTER
Original Assignee
Vifor (International) Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vifor (International) Ag filed Critical Vifor (International) Ag
Publication of PL4126854T3 publication Critical patent/PL4126854T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
PL21712874.3T 2020-03-24 2021-03-23 Sposób wytwarzania inhibitorów ferroportyny PL4126854T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20165358 2020-03-24
PCT/EP2021/057424 WO2021191202A1 (en) 2020-03-24 2021-03-23 Process for the production of ferroportin inhibitors

Publications (1)

Publication Number Publication Date
PL4126854T3 true PL4126854T3 (pl) 2026-03-30

Family

ID=69960480

Family Applications (1)

Application Number Title Priority Date Filing Date
PL21712874.3T PL4126854T3 (pl) 2020-03-24 2021-03-23 Sposób wytwarzania inhibitorów ferroportyny

Country Status (11)

Country Link
US (1) US20230212159A1 (pl)
EP (2) EP4126854B1 (pl)
JP (2) JP7726905B2 (pl)
KR (1) KR20220157395A (pl)
CN (1) CN115362154B (pl)
AU (1) AU2021243494B2 (pl)
CA (1) CA3172806A1 (pl)
ES (1) ES3056168T3 (pl)
IL (1) IL296653B1 (pl)
PL (1) PL4126854T3 (pl)
WO (1) WO2021191202A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202304896A (zh) 2021-04-22 2023-02-01 瑞士商威佛(國際)股份有限公司 經修飾的膜鐵運輸蛋白(ferroportin)抑制劑
AR127105A1 (es) * 2021-09-21 2023-12-20 Vifor Int Ag Inhibidores de ferroportina n-sustituido
WO2024083980A1 (en) 2022-10-21 2024-04-25 Vifor (International) Ag Bicyclic ferroportin inhibitors
CN121511085A (zh) 2023-06-26 2026-02-10 威佛(国际)股份公司 用于遗传性血色素沉着病(hh)的治疗的膜铁转运蛋白抑制剂
WO2026041650A1 (en) 2024-08-20 2026-02-26 Vifor (International) Ag Ferroportin-inhibitors for the use in the treatment of lupus nephritis
WO2026120152A1 (en) 2024-12-06 2026-06-11 Vifor (International) Ag Prolonged-release dosage forms of ferroportin inhibitors for use in treating hereditary haemochromatosis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6933308B2 (en) * 2002-12-20 2005-08-23 Bristol-Myers Squibb Company Aminoalkyl thiazole derivatives as KCNQ modulators
WO2011029832A1 (de) 2009-09-09 2011-03-17 Vifor (International) Ag Neue thiazol- und oxazol-hepcidin-antagonisten
WO2016065583A1 (en) * 2014-10-30 2016-05-06 Merck Sharp & Dohme Corp. Oxazole orexin receptor antagonists
WO2017068089A2 (en) 2015-10-23 2017-04-27 Vifor (International) Ag Novel ferroportin inhibitors
JOP20180036A1 (ar) * 2017-04-18 2019-01-30 Vifor Int Ag أملاح لمثبطات فروبورتين جديدة

Also Published As

Publication number Publication date
JP2023533889A (ja) 2023-08-07
EP4126854C0 (en) 2025-12-03
JP7726905B2 (ja) 2025-08-20
KR20220157395A (ko) 2022-11-29
WO2021191202A1 (en) 2021-09-30
IL296653B1 (en) 2026-07-01
JP2025166080A (ja) 2025-11-05
AU2021243494B2 (en) 2026-07-16
CA3172806A1 (en) 2021-09-30
EP4681712A3 (en) 2026-04-22
EP4126854A1 (en) 2023-02-08
IL296653A (en) 2022-11-01
EP4681712A2 (en) 2026-01-21
EP4126854B1 (en) 2025-12-03
US20230212159A1 (en) 2023-07-06
AU2021243494A1 (en) 2022-08-25
CN115362154B (zh) 2026-04-28
CN115362154A (zh) 2022-11-18
ES3056168T3 (en) 2026-02-18

Similar Documents

Publication Publication Date Title
IL314033A (en) Ras inhibitors
IL287940A (en) Fgfr inhibitors and methods of use thereof
IL311840A (en) Ras inhibitors
EP4216951A4 (en) KRAS G12D INHIBITORS
PL4063374T3 (pl) Sposób wytwarzania l-glufosynatu
DK4337652T3 (da) NLRP3-hæmmere
DK4146348T3 (da) Inhibitorer af nek7-kinase
IL315027A (en) Inhibitors of nlrp3
PL3781563T3 (pl) Inhibitory HPK1, sposób ich wytwarzania oraz ich zastosowanie
LT4157831T (lt) Jak1 inhibitoriaus gamybos būdas
PL4046129T3 (pl) Sposób wytwarzania
JP1732325S (ja) 首飾り
PL3942107T3 (pl) Sposób wytwarzania
EP4333821A4 (en) SARS-COV-2 INHIBITORS
IL292860A (en) Allosteric egfr inhibitors and methods of use thereof
IL286485A (en) Pi4-kinase inhibitors and methods of using the same
IL299700A (en) Kcnt1 inhibitors and methods of use
EP4247372A4 (en) PLASMA KALLICREIN INHIBITORS
EP4522594A4 (en) PTPN2 INHIBITORS
PL4230634T3 (pl) Sposób otrzymywania glufosynatu-amonu
EP4226919A4 (en) FERROPTOSIS INHIBITOR
EP4210694A4 (en) PLASMA KALLICREIN INHIBITORS
PL4266504T3 (pl) Zespół zaciskowy i sposób jego wytwarzania
EP4178620A4 (en) PLASMA KALLICREIN INHIBITORS
PL4375035T3 (pl) Sposób wytwarzania paneli